Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells

PURPOSE: Rational targeted therapies are needed for treatment of ovarian cancers. Signaling kinases, Src and MAPK, are activated in high grade serous ovarian cancer (HGSOC). Here, we tested the frequency of activation of both kinases in HGSOC and the therapeutic potential of dual kinase inhibition....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Simpkins, Fiona, Jang, Kibeom, Yoon, Hyunho, Hew, Karina E., Kim, Minsoon, Azzam, Diana J., Sun, Jun, Zhao, Dekuang, Ince, Tan A., Liu, Wenbin, Guo, Wei, Wei, Zhi, Zhang, Gao, Mills, Gordon B., Slingerland, Joyce M.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6557165/
https://ncbi.nlm.nih.gov/pubmed/29959144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-3697
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars